PAVmed Inc. 8-K

What Happened

• PAVmed Inc. (PAVM) held its annual meeting on June 24, 2026; stockholders representing about 59.6% of outstanding shares were present in person or by proxy. The company reported that stockholders re-elected both of management’s Class A director nominees — Ronald M. Sparks and Timothy Baxter — and approved an amendment to the Employee Stock Purchase Plan (ESPP) and the ratification of CBIZ CPAs P.C. as the independent auditor for the year ending December 31, 2026.
• Vote tallies reported:
  • Ronald M. Sparks: 3,810,460 For; 67,490 Withheld; 457,041 Broker Non-Votes.
  • Timothy Baxter: 3,815,060 For; 62,890 Withheld; 457,041 Broker Non-Votes.
  • ESPP amendment: 3,780,854 For; 95,874 Against; 1,222 Abstain; 457,041 Broker Non-Votes.
  • Auditor ratification (CBIZ): 4,306,623 For; 25,814 Against; 2,554 Abstain.

Key Details

• Meeting date: June 24, 2026; ~59.6% of shares present or represented.
• Directors re-elected: Ronald M. Sparks and Timothy Baxter (Class A directors).
• ESPP amendments approved: increase pool from 15,774 to 215,774 shares (adding 200,000 shares) and raise the annual evergreen increase cap from 5,556 to 500,000 shares.
• Auditor ratified: CBIZ CPAs P.C. appointed for 2026.

Why It Matters

• The ESPP amendment materially increases the number of shares available for employee purchases and raises the automatic annual increase cap substantially. That change could lead to greater employee equity participation and may affect total diluted share count over time; investors should monitor future share filings for dilution impacts.
• Re-election of the two Class A directors preserves board continuity and governance stability through their next terms.
• Ratification of CBIZ as auditor is a routine but necessary corporate housekeeping item confirming the company’s choice of independent accountant for 2026.
• For full details on the ESPP terms, investors should review the Definitive Proxy Statement (filed April 30, 2026) and Annex A referenced in the filing.